Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

SIJ1777

Copy Product Info
😃Good
Catalog No. T200137Cas No. 839707-55-0

SIJ1777, a derivative of GNF-7, exhibits potent anticancer effects against melanoma cells harboring BRAFI/II/III mutations. The compound significantly inhibits the activation of MEK, ERK, and AKT. Furthermore, SIJ1777 notably induces apoptosis (cell death) and effectively prevents migration, invasion, and anchorage-independent growth of melanoma cells with BRAFI/II/III mutations.

SIJ1777

SIJ1777

Copy Product Info
😃Good
Catalog No. T200137Cas No. 839707-55-0
SIJ1777, a derivative of GNF-7, exhibits potent anticancer effects against melanoma cells harboring BRAFI/II/III mutations. The compound significantly inhibits the activation of MEK, ERK, and AKT. Furthermore, SIJ1777 notably induces apoptosis (cell death) and effectively prevents migration, invasion, and anchorage-independent growth of melanoma cells with BRAFI/II/III mutations.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
25 mg$1,6706-8 weeks6-8 weeks
50 mg$2,1806-8 weeks6-8 weeks
100 mg$2,8006-8 weeks6-8 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
SIJ1777, a derivative of GNF-7, exhibits potent anticancer effects against melanoma cells harboring BRAFI/II/III mutations. The compound significantly inhibits the activation of MEK, ERK, and AKT. Furthermore, SIJ1777 notably induces apoptosis (cell death) and effectively prevents migration, invasion, and anchorage-independent growth of melanoma cells with BRAFI/II/III mutations.
In vitro
SIJ1777 exhibits enhanced antiproliferative activity against melanoma cells (SK-MEL-2, SK-MEL-28, A375, WM3670, WM3629) compared to GNF-7, with a 2 to 14-fold increase. This enhancement is observed irrespective of the BRAF mutation status in the melanoma cells, where SIJ1777 completely inhibits the phosphorylation levels of MEK, -ERK, and -AKT at a concentration of 1 μM. Additionally, SIJ1777 increases the levels of cleaved PARP in a concentration-dependent manner in melanoma cells (SK-MEL-2, SK-MEL-28, C8161, WM3629).
Chemical Properties
Molecular Weight536.51
FormulaC26H23F3N8O2
Cas No.839707-55-0
SmilesO=C(NC1=CC=C(C(=C1)N2C(=O)N(C3=NC(=NC=C3C2)NC4=NN(C=C4)C)C)C)C5=CC=CC(=C5)C(F)(F)F
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy SIJ1777 | purchase SIJ1777 | SIJ1777 cost | order SIJ1777 | SIJ1777 chemical structure | SIJ1777 in vitro | SIJ1777 formula | SIJ1777 molecular weight